Clinical Trial Update: Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial update of AZD1775 combined with paclitaxel in advanced gastric adenocarcinoma with TP53 mutation as second-line therapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma

Drugs mentioned

• AZD1775 (Adavosertib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Samsung Medical Center | Conditions: Advanced Gastric Adenocarcinoma | Phase 2 | Status: COMPLETED